Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited
Your view on RGC
Overview
What the company does, where it operates, and who runs it.
About Regencell Bioscience Holdings Limited
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Yat-Gai Au
- Headquarters
- First Commercial Building, Causeway Bay, HK
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Yat-Gai Au
- Headquarters
- First Commercial Building, Causeway Bay, HK
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.
The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Regencell Bioscience Holdings Limited, and the rating behind it. RGC last traded at $5.64; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Regencell Bioscience Holdings Limited. Starting points for Regencell Bioscience Holdings Limited: EPS -$0.01, beta 1.43 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Regencell Bioscience Holdings Limited. Regencell Bioscience Holdings Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Regencell Bioscience Holdings Limited. Trailing twelve-month EPS for Regencell Bioscience Holdings Limited stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Regencell Bioscience Holdings Limited. Regencell Bioscience Holdings Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Regencell Bioscience Holdings Limited valued side by side against its closest peers. Regencell Bioscience Holdings Limited is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Regencell Bioscience Holdings Limited, and how their positions are changing. At a $2.79B market value, institutional positions materially move Regencell Bioscience Holdings Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Regencell Bioscience Holdings Limited executives and directors. Shares of Regencell Bioscience Holdings Limited have traded between $0.09 and $83.60 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Regencell Bioscience Holdings Limited. Regencell Bioscience Holdings Limited is a $2.79B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Regencell Bioscience Holdings Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Regencell Bioscience Holdings Limited. Coverage tracks Regencell Bioscience Holdings Limited within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.